BLCM Документы SEC - Bellicum Pharmaceuticals, Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

LEI	529900HBXNLX2TBQZQ65
CIK	1358403

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bellicum Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

November 14, 2024	SC 13G/A	BLCM / Bellicum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-blcm093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen
March 1, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36783 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specif
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	POS AM	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	POS AM	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	POS AM	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	POS AM	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	POS AM	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
February 23, 2024	EX-10.1	AMENDMENT NO. 1 TO CONSULTING AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO CONSULTING AGREEMENT THIS AMENDMENT NO. 1 TO CONSULTING AGREEMENT (this “Amendment”) is effective as of December 31, 2023 (the “Effective Date”) by and between Bellicum Pharmaceuticals, Inc., (the “Company”) and Richard Fair (the “Consultant”). RECITALS WHEREAS, the Company and Consultant are parties to that certain Consulting Agreement, effective as of June 30, 202
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	POS AM	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Nos.
February 21, 2024	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
February 14, 2024	SC 13G/A	BLCM / Bellicum Pharmaceuticals, Inc. / Ikarian Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box t
February 14, 2024	SC 13G/A	BLCM / Bellicum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
January 30, 2024	EX-99.1	Bellicum Pharmaceuticals, Inc. 3730 Kirby Drive, Ste. 120 Houston, TX 77098 (281) 454-3424 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE RECONVENED ON FEBRUARY 20, 2024 Exhibit 99.1 Bellicum Pharmaceuticals, Inc. 3730 Kirby Drive, Ste. 120 Houston, TX 77098 (281) 454-3424 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE RECONVENED ON FEBRUARY 20, 2024 Notice is hereby given that the special meeting of stockholders of Bellicum Pharmaceuticals, Inc., a Delaware corporation (“Bellicum,” “we,” “us” or “our”), originally convened and adjourned on January 24, 2024, will
January 30, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
January 24, 2024	EX-3.2	AMENDMENT TO AMENDED AND RESTATED BELLICUM PHARMACEUTICALS, INC. Exhibit 3.2 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF BELLICUM PHARMACEUTICALS, INC. The Amended and Restated Bylaws (the “Bylaws”) of Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are hereby amended as follows: Article III, Section 8 of the Bylaws is hereby amended and restated in its entirety as follows: “Section 8. Quorum. At all meetings of stockholders, except wher
January 24, 2024	EX-3.1	CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PREFERRED STOCK OF BELLICUM PHARMACEUTICALS, INC. Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PREFERRED STOCK OF BELLICUM PHARMACEUTICALS, INC. Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), does hereby certify that, pursuant to the authority conferred upon the Board of Directors by the Amended and Restated Certificate of Incorporation of the Corporation (as amended and/or restated from time to time, the
January 24, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
December 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Bellicum Pharma UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
December 14, 2023	EX-99.1	Bellicum Pharmaceuticals, Inc. 3730 Kirby Drive, Ste. 1200 Houston, TX 77098 Exhibit 99.1 THE INFORMATION CONTAINED IN THIS INFORMATION STATEMENT AND THE EXHIBITS ATTACHED HERETO ARE BEING PROVIDED TO THE STOCKHOLDERS OF BELLICUM PHARMACEUTICALS, INC., A DELAWARE CORPORATION, FOR THE PURPOSE OF DISCLOSING RELEVANT INFORMATION ABOUT THE ASSET SALE PROPOSAL, THE DISSOLUTION PROPOSAL AND CERTAIN OTHER RELATED MATTERS DESCRIBED HEREIN. THE INFORMATION CONTAINED IN THIS INFORMA
November 24, 2023	SC 13D/A	BLCM / Bellicum Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
November 24, 2023	EX-99.1	WAiver Agreement EX-99.1 2 tm2331324d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 EXECUTION VERSION WAiver Agreement This WAIVER AGREEMENT (this “Agreement”) is made as of November 21, 2023, by and among Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each Person set forth on Schedule A-1 hereto (each, a “Securityholder” and collectively, the “Securityholders”). WHEREAS, the Company and each o
November 22, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 (November 21, 2023) Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction
November 22, 2023	EX-2.1	ASSET PURCHASE AGREEMENT by and between Bellicum Pharmaceuticals, Inc. The University of Texas M. D. Anderson Cancer Center Dated as of November 21, 2023 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
November 14, 2023	EX-10.1	Amendment to Consulting Agreement, dated as of September 26, 2023, by and between the Registrant and Charity Scripture. AMENDMENT TO CONSULTING AGREEMENT This Amendment to Consulting Agreement (the “Amendment”) is made and entered into effective September 26, 2023 (the “Effective Date”) by and between Charity Scripture, having an address on file (“Consultant”) and Bellicum Pharmaceuticals, Inc.
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION R Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
September 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 Bellicum Pharm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (
September 29, 2023	EX-10.1	Amendment to Consulting Agreement by and between the Company and Charity D. Scripture, dated September 26 AMENDMENT TO CONSULTING AGREEMENT This Amendment to Consulting Agreement (the “Amendment”) is made and entered into effective September 26, 2023 (the “Effective Date”) by and between Charity Scripture, having an address on file (“Consultant”) and Bellicum Pharmaceuticals, Inc.
August 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Bellicum Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Com
August 10, 2023	EX-10.1	Consulting Agreement by and between the Registrant and Richard A. Fair, dated June 30, 2023 Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of June 30, 2023 (“Effective Date”) by and between Bellicum Pharmaceuticals, Inc. a Delaware corporation having its principal place of business at 3730 Kirby Drive, Suite 1200, Houston, Texas 77098 (collectively with its subsidiaries, “Bellicum” or the “Company”), and Richard Fair, having an a
August 10, 2023	EX-10.2	Consulting Agreement by and between the Registrant and Charity D. Scripture, dated June 30, 2023 Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of July 1, 2023 (“Effective Date”) by and between Bellicum Pharmaceuticals, Inc. a Delaware corporation having its principal place of business at 3730 Kirby Drive, Suite 1200, Houston, Texas 77098 (collectively with its subsidiaries, “Bellicum” or the “Company”), and Charity Scripture, having
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
June 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 Bellicum Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commis
May 30, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commis
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPOR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
May 5, 2023	SC 13D	BLCM / Bellicum Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
May 5, 2023	EX-99.1	Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons. Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Bellicum Pharmaceuticals, Inc. This Agreement may be executed in any nu
April 28, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36
April 11, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36783 Bellicum Pharma
March 31, 2023	EX-4.6	Description of EX-4.6 2 exhibit46-descriptionofcom.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF COMMON STOCK General The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended
March 31, 2023	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Bellicum Pharmaceuticals, Inc. as of December 31, 2022 Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom Bellicum Pharma GmbH, a private limited liability company organized under the laws of Germany
March 31, 2023	EX-10.5(A)	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended Exhibit 10.5(A) Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: April 22, 2019 Approved by the Stockholders: June 13, 2019 Amended and Approved by the Board of Directors: July 9, 2019 Amended by the Board of Directors: December 2, 2019 Approved by the Stockholders: January 15, 2020 Amended by the Board of Directors: April 1
February 14, 2023	EX-99.1	JOINT FILING AGREEMENT February 14, 2023 EX-99.1 2 d417970dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule o
February 14, 2023	SC 13G/A	BLCM / Bellicum Pharmaceuticals Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment SC 13G/A 1 d417970dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statemen
February 14, 2023	SC 13G/A	BLCM / Bellicum Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-blcm123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement
February 9, 2023	SC 13G/A	BLCM / Bellicum Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Bellicum Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 079481404 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule i
December 12, 2022	EX-3.1	Amended and Restated Certificate of Incorporation, as amended by Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant and the Second Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant and the Third Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-k (File No. 001-36783), filed with the SEC on December 12, 2022). Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BELLICUM PHARMACEUTICALS, INC Thomas J. Farrell hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Bellicum Pharmaceuticals, Inc., a Delaware corporation. TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was July 14, 2004, un
December 12, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Bellicum Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
December 7, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Bellicum Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
November 18, 2022	SC 13D	BLCM / Bellicum Pharmaceuticals Inc / BELLICUM PHARMACEUTICALS, INC - SC 13D Activist Investment SC 13D 1 bellicum-schedule13dxrickf.htm SC 13D CUSIP No. 079481404 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bellicum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) Richard A. Fair Chief Executive Officer Bell
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
November 10, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Bellicum Pharma UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
November 10, 2022	EX-99.1	Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update Exhibit 99.1 Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update HOUSTON, November 10, 2022 - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update. “We are encouraged by the progress we are makin
October 24, 2022	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
October 24, 2022	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
October 14, 2022	PRE 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PRE 14A 1 specialmeetingproxydecembe.htm PRE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Com
August 11, 2022	EX-10.1	Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy. Exhibit 10.1 BELLICUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Bellicum Pharmaceuticals, Inc. (?Bellicum?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her B
August 11, 2022	EX-99.1	Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update Exhibit 99.1 Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update HOUSTON, August 11, 2022 - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update. ?We have continued to make progress with our pat
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
August 11, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 2 exhibit107august2022.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bellicum Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fe
August 11, 2022	S-8	As filed with the Securities and Exchange Commission on August 11, 2022 S-8 1 bellicum-formsx8august2022.htm S-8 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1450200 (State or other jurisd
June 16, 2022	EX-10.1	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended. Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: April 22, 2019 Approved by the Stockholders: June 13, 2019 Amended and Approved by the Board of Directors: July 9, 2019 Amended by the Board of Directors: December 2, 2019 Approved by the Stockholders: January 15, 2020 Amended by the Board of Directors: April 16, 2020 Amended
June 16, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
May 19, 2022	CORRESP	Bellicum Pharmaceuticals, Inc. 3730 Kirby Drive, Suite 1200 Houston, TX 77030 CORRESP 1 filename1.htm Bellicum Pharmaceuticals, Inc. 3730 Kirby Drive, Suite 1200 Houston, TX 77030 May 19, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Michael Davis Re: Bellicum Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 Filed: May 13, 2022 File No. 333-264939 Ladies
May 13, 2022	EX-FILING FEES	iling Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bellicum Pharmaceuticals, Inc.
May 13, 2022	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. EXHIBIT 4.7 Bellicum Pharmaceuticals, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Bellicum Pharmaceuticals, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between Bellicum Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking associat
May 13, 2022	EX-10.1	Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-3 (File No. 333-264939), filed with SEC on May 13, 2022). Exhibit 10.1 BELLICUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Bellicum Pharmaceuticals, Inc. (?Bellicum?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her B
May 13, 2022	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 Bellicum Pharmaceuticals, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Bellicum Pharmaceuticals, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Bellicum Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga
May 13, 2022	EX-4.3	Form of Indenture, between the Registrant and one or more trustees to be named. EXHIBIT 4.3 BELLICUM PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate
May 13, 2022	S-3	As filed with the Securities and Exchange Commission on May 13, 2022 As filed with the Securities and Exchange Commission on May 13, 2022 Registration No.
May 13, 2022	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 Bellicum Pharmaceuticals, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Bellicum Pharmaceuticals, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Bellicum Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking associat
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commis
May 12, 2022	EX-99.1	Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update Exhibit 99.1 Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update HOUSTON, May 12, 2022 - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update. ?I am pleased with the growing momentum in patient re
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
April 29, 2022	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 29, 2022	DEF 14A	Schedule 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
March 24, 2022	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Bellicum Pharmaceuticals, Inc. as of December 31, 2021 Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom Bellicum Pharma GmbH, a private limited liability company organized under the laws of Germany
March 24, 2022	EX-99.1	Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update - Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Exhibit 99.1 Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update - Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid tumors - - Previously reported $35 million private pl
March 24, 2022	EX-10.25	(incorporated by reference to Exhibit 10.25 to the Registrant’s Annual Report on Form 10-K (File No. 001-36783), filed with the SEC on March 24, 2022). Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version MASTER SERVICES AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER AND BELLICUM PHARMACEUTICALS, INC. This Master Services Agreement (?Agreem
March 24, 2022	EX-10.26	as of November 3, 2021 (incorporated by reference to Exhibit 10.26 to the Registrant’s Annual Report on Form 10-K (File No. 001-36783), filed with the SEC on March 24, 2022). Exhibit 10.26 BELLICUM PHARMACEUTICALS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) dated as of November 3, 2021, is entered into by and between Bellicum Pharmaceuticals, Inc. a Delaware corporation, having a location at 3730 Kirby Drive, Suite 1200, Houston, Texas 77098 (the ?Company?) and Charity Scripture, MS, PharmD, BCOP. (th
March 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36783 Bellicum Pharma
February 15, 2022	SC 13G/A	BLCM / Bellicum Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 15, 2022	EX-99.A	Exhibit A EX-99.A 2 d304203dex99a.htm EXHIBIT A Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01 per share, of Bellicum Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd
February 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
February 14, 2022	SC 13G/A	BLCM / Bellicum Pharmaceuticals Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT February 14, 2022 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a
February 9, 2022	SC 13G	BLCM / Bellicum Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Bellicum Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 079481404 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-
December 13, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
December 9, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
December 6, 2021	EX-99.1	Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, our CaspaCIDe safety switch, an Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO December 2021 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR? platform, our CaspaCIDe safety switch, and related technologies; our product candidates includin
December 6, 2021	EX-4.1	Form of Pre-Funded Warrant issued in private placement (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on December 6, 2021). Exhibit 4.1 Form of Warrant PRE-FUNDED COMMON STOCK PURCHASE WARRANT BELLICUM PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
December 6, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
December 6, 2021	EX-4.2	Form of Accompanying Common Warrant issued in private placement (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on December 6, 2021). Exhibit 4.2 [FORM OF WARRANT] BELLICUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [] Number of Shares of Common Stock: [] Date of Issuance: December , 2021 (?Issuance Date?) Expiration Date: December , 2028 (?Expiration Date?) Bellicum Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and
December 6, 2021	EX-10.1	Securities Purchase Agreement dated December 4, 2021, by and among the Company, Baker Brothers Life Sciences, LP, and Boxer Capital, LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36783), filed with the SEC on December 6, 2021). EX-10.1 4 d215852dex101.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made and entered into as of December 4, 2021 (the “Effective Date”) by and among Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the signature pages hereto (each a “Purchaser” and together the “Purchasers”). Cer
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
November 4, 2021	EX-99.1	Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update - Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scri Exhibit 99.1 Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update - Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe? safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, November 4, 2021 - Bellicum Pharmaceuticals,
November 4, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
September 13, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (
September 13, 2021	EX-99.1	Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, our CaspaCIDe safety switch, an Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO September 2021Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO September 2021 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR?
August 13, 2021	S-8	As filed with the Securities and Exchange Commission on August 12, 2021 As filed with the Securities and Exchange Commission on August 12, 2021 Registration No.
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Com
August 12, 2021	EX-10.2	License Agreement by and between the Registrant and BioVec Pharma, Inc., dated as of June 4, 2015. Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE BELLICUM PHARMACEUTICALS, INC. HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BELLICUM PHARMACEUTICALS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT This LICENSE AGREEMENT (the ?Agreement?), effective as of June 4, 2015 (the ?Effective Date?), is m
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
August 12, 2021	EX-99.1	Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update - Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continu Exhibit 99.1 Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update - Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe? safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic prostate cancer an
June 17, 2021	EX-10.1	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended. Exhibit 10.1 BELLICUM PHARMACEUTICALS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: APRIL 22, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2019 AMENDED AND APPROVED BY THE BOARD OF DIRECTORS: JULY 9, 2019 AMENDED BY THE BOARD OF DIRECTORS: DECEMBER 2, 2019 APPROVED BY THE STOCKHOLDERS: JANUARY 15, 2020 AMENDED BY THE BOARD OF DIRECTORS: APRIL 16,
June 17, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
May 17, 2021	EX-99.1	Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update Exhibit 99.1 Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update HOUSTON, May 17, 2021 - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update. ?In the first quarter, Bellicum maintained focus on t
May 17, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commis
May 14, 2021	EX-10.1	Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy. Exhibit 10.1 BELLICUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Bellicum Pharmaceuticals, Inc. (?Bellicum?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her B
May 14, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
May 7, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commiss
April 30, 2021	DEFA14A	- DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 30, 2021	DEF 14A	Schedule 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 31, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36783 Bellicum Pharma
March 31, 2021	EX-10.5B	Forms of stock option grant notice, stock option agreement and notice of exercise, and forms of restricted stock award notice and restricted stock award agreement under the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan. Exhibit 10.5(B) STANDARD FORM BELLICUM PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2019 EQUITY INCENTIVE PLAN) Bellicum Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2019 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions a
March 31, 2021	EX-21	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Bellicum Pharmaceuticals, Inc. as of December 31, 2020 Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom Bellicum Pharma GmbH, a private limited liability company organized under the laws of Germany
March 30, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
March 30, 2021	EX-99	Bellicum Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation tr Exhibit 99.1 Bellicum Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic prostate or pancreatic cancer Conference call and web
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Bellicum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securi SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Bellicum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 079481107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa
February 9, 2021	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
February 9, 2021	EX-99.1	Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, and related technologies; our p EX-99.1 Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO February 2021Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO February 2021 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our G
January 11, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class o SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BELLICUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481404 (CUSIP Number) December 24, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d
January 11, 2021	EX-99.1	JOINT FILING AGREEMENT January 8, 2021 EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT January 8, 2021 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (inclu
January 11, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Com
November 27, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C
November 5, 2020	EX-99.1	Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Compl Exhibit 99.1 Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common stock plus warrants that raised gross proceeds of approximately $25 million HOUSTON, November 5, 2020 -
November 5, 2020	EX-10.2	Omnibus Amendment Agreement, dated October 3, 2014, by and between Registrant and ARIAD Pharmaceuticals, Inc. Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. OMNIBUS AMENDMENT AGREEMENT THIS OMNIBUS AMENDMENT AGREEMENT (“Agreement”) is entered into and made effective as of October 3, 2014 (the “Effective Date”) by and between ARIAD PHARMACEUT
November 5, 2020	EX-10.3	Exclusive License Agreement, dated March 20, 2008, by and between the Registrant and Baylor College of Medicine. Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Exclusive License Agreement BAYLOR COLLEGE OF MEDICINE BELLICUM PHARMACEUTICALS, INC. RE: 1. OTA # 01.085, entitled “Induced CD40 Activation in Dendritic Cell-based Prostate Cancer Vacci
November 5, 2020	EX-10.6	Exclusive License Agreement, effective November 1, 2014, by and between the Registrant and Baylor College of Medicine. Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT Re: BCM BLG # 13-040 Entitled “Methods for Inducing Selective Apoptosis” This Exclusive License Agreement (hereinafter called “Agreement”), to be effective as
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
November 5, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
November 5, 2020	EX-10.1	, dated March 7, 2011, by and between the Registrant and ARIAD Pharmaceuticals, Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is made effective as of March 7, 2011 (the “Effective Date”) by and between ARIAD Ph
November 5, 2020	EX-10.4	Exclusive License Agreement, dated June 27, 2010, by and between the Registrant and Baylor College of Medicine. Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BAYLOR COLLEGE OF MEDICINE BELLICUM PHARMACEUTICALS, INC. RE: BLG 06-028, “Inducible Toll-like Receptors and Composite Costimulatory Receptors for Unified, Br
November 5, 2020	EX-10.5	Cancer Research Grant Contract, dated July 27, 2011, by and between the Registrant and the Cancer Prevention and Research Institute of Texas. Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. STATE OF TEXAS COUNTY OF TRAVIS This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred t
November 2, 2020	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
November 2, 2020	EX-4.2	Form of warrant to purchase common stock. EX-4.2 Exhibit 4.2 [FORM OF WARRANT] BELLICUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: November 3, 2020 (“Issuance Date”) Expiration Date: November 3, 2025 (“Expiration Date”) Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the r
November 2, 2020	EX-4.1	Form of pre-funded warrant. EX-4.1 Exhibit 4.1 Form of Warrant PRE-FUNDED COMMON STOCK PURCHASE WARRANT BELLICUM PHARMACEUTICALS, INC. Warrant Shares: Issue Date:, 2020 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
November 2, 2020	EX-99.1	Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market EX-99.1 Exhibit 99.1 Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market October 29, 2020 17:16 ET \| Source: Bellicum Pharmaceuticals, Inc. HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-t
November 2, 2020	EX-1.1	Underwriting Agreement, dated October 29, 2020, by and between Bellicum Pharmaceuticals and H.C. Wainwright & Co. EX-1.1 Exhibit 1.1 1,040,000 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 3,109,378 SHARES OF COMMON STOCK COMMON WARRANTS TO PURCHASE 4,149,378 SHARES OF COMMON STOCK BELLICUM PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT October 29, 2020 H.C. Wainwright & Co., LLC As Representative of the several Underwriters listed in Schedule V hereto 430 Park Avenue, 4th Floor New York, NY 10022 Ladi
October 30, 2020	424B5	1,040,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,109,378 Shares of Common Stock Warrants to Purchase up to 4,149,378 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232771 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2019) 1,040,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,109,378 Shares of Common Stock Warrants to Purchase up to 4,149,378 Shares of Common Stock We are offering 1,040,000 shares of our common stock and common warrants to purchase an equal numbe
October 29, 2020	EX-99.1	Bellicum Announces Interim BPX-601 Data and Corporate Restructuring EX-99.1 Exhibit 99.1 Bellicum Announces Interim BPX-601 Data and Corporate Restructuring HOUSTON, October 29, 2020 — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory metastatic pancreatic cancer. Findings fro
October 29, 2020	EX-99.2	Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, and related technologies; our p EX-99.2 Investor Presentation Building a powerful new future in cellular IO October 2020 Exhibit 99.2 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, and related technologies; our product candidates including BPX-601, BPX-603, an
October 29, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
September 16, 2020	EX-14.1	Bellicum Pharmaceuticals, Inc. Code of Business Conduct and Ethics Exhibit 14.1 Bellicum Pharmaceuticals, Inc. Code of Business Conduct and Ethics Introduction Bellicum Pharmaceuticals, Inc. (the “Company”) is committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (this “Code”) reflects the business practices and principles of behavior that support this commitment. We expect every employee, officer
September 16, 2020	8-K/A	Submission of Matters to a Vote of Security Holders - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Com
September 16, 2020	8-K	Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (
August 6, 2020	EX-10.1	Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy. Exhibit 10.1 BELLICUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Bellicum Pharmaceuticals, Inc. (“Bellicum”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her B
August 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
August 6, 2020	EX-99.1	Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical Exhibit 99.1 Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 Management to host conference call and webcast today at 5 p.m. ET / 2 p.m. PT HOUSTON, August 6, 2020 - Bellic
August 6, 2020	EX-10.2	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended. Exhibit 10.2 Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: April 22, 2019 Approved by the Stockholders: June 13, 2019 Amended and Approved by the Board of Directors: July 9, 2019 Amended by the Board of Directors: December 2, 2019 Approved by the Stockholders: January 15, 2020 Amended by the Board of Directors: April 16,
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
August 6, 2020	S-8	- S-8 As filed with the Securities and Exchange Commission on August 6, 2020 Registration No.
August 6, 2020	EX-3.1	Amended and Restated Certificate of Incorporation, as amended by the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant and the Second Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BELLICUM PHARMACEUTICALS, INC Thomas J. Farrell hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Bellicum Pharmaceuticals, Inc., a Delaware corporation. TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was July 14, 2004, un
June 24, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
June 17, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
June 17, 2020	EX-3.1	Second Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellicum Pharmaceuticals, Inc. exh31-bellicumpharmaceut Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “BELLICUM PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF JUNE, A.D. 2020, AT 8:23 O`CLOCK P.M. 3829024 8100 Authentication: 203115158 SR# 20205708351 Date: 06-1
June 3, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commis
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commiss
May 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
May 7, 2020	EX-99.1	Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply Exhibit 99.1 Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement HOUSTON, May 7, 2020 - Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immuno
May 7, 2020	EX-10.1	Second Amendment to Loan and Security Agreement, dated March 31, 2020, by and between the Registrant and Oxford Finance LLC. Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of March 31, 2020, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Le
May 1, 2020	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
April 27, 2020	DEF 14A	Schedule 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 27, 2020	DEFA14A	- DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 17, 2020	8-K	Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
April 17, 2020	PRE 14A	BLCM / Bellicum Pharmaceuticals, Inc. PRE 14A - - PRE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 13, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
April 6, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
March 12, 2020	EX-3.1	Amended and Restated Certificate of Incorporation, as amended by Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant and the Second Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report Form 10-Q with the SEC on August 6, 2020). Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BELLICUM PHARMACEUTICALS, INC Thomas J. Farrell hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Bellicum Pharmaceuticals, Inc., a Delaware corporation. TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was July 14, 2004, un
March 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
March 12, 2020	EX-10.6	Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy. EX-10.6 4 exhibit106directorcompens.htm EXHIBIT 10.6 Exhibit 10.6 BELLICUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Bellicum Pharmaceuticals, Inc. (“Bellicum”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-E
March 12, 2020	EX-99.1	Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreeme Exhibit 99.1 Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson HOUSTON, March 12, 2020 - Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing
March 12, 2020	EX-10.5(B)	Forms of stock option grant notice, stock option agreement and notice of exercise, and forms of restricted stock award notice and restricted stock award agreement under the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan. Exhibit 10.5(B) STANDARD FORM BELLICUM PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2019 EQUITY INCENTIVE PLAN) Bellicum Pharmaceuticals, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions a
March 12, 2020	EX-10.35	First Amendment to Loan and Security Agreement, dated December 24, 2019, by and between the Registrant and Oxford Finance LLC. Exhibit 10.35 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 24, 2019, by and between
March 12, 2020	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Bellicum Pharmaceuticals, Inc. as of December 31, 2019 Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom Bellicum Pharma GmbH, a private limited liability company organized under the laws of Germany
March 12, 2020	EX-10.39	First Amendment to Asset Purchase Agreement, dated February 21, 2020, by and between the Registrant and The University of Texas M.D. Anderson Cancer Center Exhibit 10.39 Execution Version FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT THIS FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”) is entered into as of February 21, 2020, by and between Bellicum Pharmaceuticals, Inc., a Delaware corporation (“Seller”), and The University of Texas M.D. Anderson Cancer Center, an institution of higher education and an agency of the State of Texas (“Buy
March 12, 2020	EX-10.38	Asset Purchase Agreement, dated January 17, 2020, by and between the Registrant and The University of Texas M.D. Anderson Cancer Center Exhibit 10.38 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely be competitively harmful if publicly disclosed. Execution Version ASSET PURCHASE AGREEMENT by and between Bellicum Pharmaceuticals, Inc., as Seller, and The University of Texas M.D. Anderson Cancer Center, as Buyer January
March 12, 2020	EX-4.7	Description of Securities Exhibit 4.7 DESCRIPTION OF COMMON STOCK General The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated certificate of incorporation (the
March 12, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36783 Bellicum Pharma
February 14, 2020	SC 13G/A	BLCM / Bellicum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 6, 2020	8-K	Termination of a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation)
February 5, 2020	EX-3.1	Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated as of February 5, 2020. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BELLICUM PHARMACEUTICALS, INC. Bellicum Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: First: The name of the Company is BELLICUM PHARMACEUTICALS, INC. Second: The date of fi
February 5, 2020	EX-99.1	Bellicum Announces Reverse Stock Split Exhibit 99.1 Bellicum Announces Reverse Stock Split HOUSTON, February 5, 2020 - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reve
February 5, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
January 29, 2020	S-8	January 29, 2020 (File No. 333-236149) As filed with the Securities and Exchange Commission on January 29, 2020 Registration No.
January 29, 2020	EX-99.1	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended. Exhibit 99.1 BELLICUM PHARMACEUTICALS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: APRIL 22, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2019 AMENDED AND APPROVED BY THE BOARD OF DIRECTORS: JULY 9, 2019 AMENDED BY THE BOARD OF DIRECTORS: DECEMBER 2, 2019 APPROVED BY THE STOCKHOLDERS: JANUARY 15, 2020 1. GENERAL. (a) Successor to and Continuation
January 24, 2020	SC 13D/A	BLCM / Bellicum Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
January 21, 2020	8-K	Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
January 15, 2020	EX-99.1	Investor Presentation Building a powerful new future in cellular IO January 2020 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and develo bellicuminvdeckjan20v8 Investor Presentation Building a powerful new future in cellular IO January 2020 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ (incorporating “iMC”), GoCAR-T ® CaspaCIDe® (“iC9”), and related technologies; our prod
January 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
January 14, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation)
December 31, 2019	8-K	Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation
December 19, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation
December 5, 2019	DEF 14A	BLCM / Bellicum Pharmaceuticals, Inc. DEF 14A - - DEF 14A DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
December 5, 2019	DEFA14A	BLCM / Bellicum Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 25, 2019	PRE 14A	BLCM / Bellicum Pharmaceuticals, Inc. PRE 14A - - PRE 14A PRE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 6, 2019	10-Q	BLCM / Bellicum Pharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
November 6, 2019	EX-99.1	Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy Exhibit 99.1 Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to extend runway to meaningful GoCAR data readouts HOUSTON, November 6, 2019 - Bellicum Pharmac
November 6, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Co
September 6, 2019	SC 13G/A	BLCM / Bellicum Pharmaceuticals, Inc. / JP Morgan Chase & Co Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* Bellicum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 079481107 (CUSIP Number) August 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
August 26, 2019	SC 13G	BLCM / Bellicum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
August 26, 2019	SC 13G	BLCM / Bellicum Pharmaceuticals, Inc. / Boxer Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bellicum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 079481107 (CUSIP Number) August 16, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
August 26, 2019	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of Bellicum Pharmaceuticals, Inc., par value $0.01, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as
August 22, 2019	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Bellicum Pharmaceuticals, Inc. This Agreement may be executed in any nu
August 22, 2019	SC 13D	BLCM / Bellicum Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
August 19, 2019	EX-4.2	Form of Warrant issued in private offering (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K (File No. 001-36783), filed with the SEC on August 19, 2019). EX-4.2 Exhibit 4.2 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SE
August 19, 2019	EX-3.1	Certificate of Designations, Preferences and Rights of Series 1 Redeemable Convertible Non-Voting Preferred Stock, Series 2 Redeemable Convertible Non-Voting Preferred Stock and Series 3 Redeemable Convertible Non-Voting Preferred Stock of Bellicum Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s report on Form 8-K, filed with the SEC on August 19, 2019). EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES 1 REDEEMABLE CONVERTIBLE NON-VOTING PREFERRED STOCK SERIES 2 REDEEMABLE CONVERTIBLE NON-VOTING PREFERRED STOCK AND SERIES 3 REDEEMABLE CONVERTIBLE NON-VOTING PREFERRED STOCK OF BELLICUM PHARMACEUTICALS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Bellicum Pharmaceuticals, Inc., a Delaware co
August 19, 2019	EX-99.2	Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of EX-99.2 Exhibit 99.2 Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent Private Placement of up to $70.0 Million
August 19, 2019	EX-1.1	Underwriting Agreement, dated August 16, 2019, by and among the Company, Jefferies LLC and Wells Fargo Securities, LLC, as representative of the several underwriters identified therein. EX-1.1 Exhibit 1.1 Execution Version 575,000 Shares of Series 1 Preferred Stock Warrants Bellicum Pharmaceuticals, Inc. UNDERWRITING AGREEMENT August 16, 2019 JEFFERIES LLC WELLS FARGO SECURITIES, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o WELLS FARGO SECURITIES, LLC 375 Park Avenue New York, NY 10152 Ladies and Gentlemen: I
August 19, 2019	EX-4.1	Form of Warrant issued in public offering (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-36783), filed with the SEC on August 19, 2019). EX-4.1 Exhibit 4.1 [FORM OF WARRANT] BELLICUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK OR SERIES 1 PREFERRED STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: August 21,2019 (“Issuance Date”) Expiration Date: August 21, 2026 (“Expiration Date”) Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valu
August 19, 2019	EX-99.1	Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement EX-99.1 Exhibit 99.1 Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc.(Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it is offeri
August 19, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (
August 19, 2019	EX-10.1	Securities Purchase Agreement, dated August 16, 2019, by and among the Company and the institutional investors named therein, (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-36783), filed with the SEC on August 19, 2019). EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made and entered into as of August 16, 2019 (the “Effective Date”) by and among Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the signature pages hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not other
August 19, 2019	424B5	$57,500,000 Series 1 Redeemable Convertible Non-Voting Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232771 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2019) $57,500,000 Series 1 Redeemable Convertible Non-Voting Preferred Stock Warrants We are offering 575,000 shares of Series 1 redeemable convertible non-voting preferred stock, or the Series 1 preferred stock, and warrants to purchase up to an aggregate of 57,
August 16, 2019	FWP	Pricing Term Sheet Bellicum Pharmaceuticals, Inc. Series 1 Redeemable Convertible Non-Voting Preferred Stock FWP Issuer Free Writing Prospectus dated August 16, 2019 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No.
August 16, 2019	424B5	SUBJECT TO COMPLETION, DATED AUGUST 16, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232771 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is
August 15, 2019	FWP	Preliminary Term Sheet Bellicum Pharmaceuticals, Inc. Series 1 Redeemable Convertible Non-Voting Preferred Stock FWP Issuer Free Writing Prospectus dated August 15, 2019 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No.
August 5, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Comm
August 5, 2019	EX-99.1	Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary e Exhibit 99.1 Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial HOUSTON, August 5, 2019 - Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in devel
August 5, 2019	10-Q	August 5, 2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
July 29, 2019	EX-99.1	Investor Presentation Striving to deliver cures through controllable cell therapy July 2019 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research investorpresentationjuly Investor Presentation Striving to deliver cures through controllable cell therapy July 2019 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our CaspaCIDe® (“iC9”), GoCAR-T ® (incorporating “iMC”) and related technologies; our
July 29, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (Commi
July 26, 2019	CORRESP	BLCM / Bellicum Pharmaceuticals, Inc. CORRESP - - CORRESP BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD, STE. 800 HOUSTON, TX 77030 July 26, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook Re: Bellicum Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-232771) Acceleration Request Requested
July 23, 2019	S-8	July 23, 2019 (File No. 333-232774) S-8 As filed with the Securities and Exchange Commission on July 23, 2019 Registration No.
July 23, 2019	EX-99.1	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan and forms of stock option grant notice, stock option agreement and notice of exercise, and forms of restricted stock award notice and restricted stock award agreement thereunder. EX-99.1 Exhibit 99.1 BELLICUM PHARMACEUTICALS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: APRIL 22, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2019 AMENDED AND APPROVED BY THE BOARD OF DIRECTORS: JULY 9, 2019 1. GENERAL. (a) Successor to and Continuation of 2014 Plan. (i) The Plan is intended as the successor to and continuation of the Bellicu
July 23, 2019	EX-4.3	Form of Indenture, between the Registrant and one or more trustees to be named. EX-4.3 EXHIBIT 4.3 BELLICUM PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ • ], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s C
July 23, 2019	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 Exhibit 4.5 BELLICUM PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 1 BELLICUM PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between BELLICUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association]
July 23, 2019	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 BELLICUM PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 1 BELLICUM PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between BELLICUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking asso
July 23, 2019	S-3	BLCM / Bellicum Pharmaceuticals, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 23, 2019 Registration No.
July 23, 2019	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 BELLICUM PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 1 BELLICUM PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between BELLICUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking asso
June 24, 2019	EX-99.1	Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan and forms of stock option grant notice, stock option agreement and notice of exercise, and forms of restricted stock award notice and restricted stock award agreement thereunder. EX-99.1 Exhibit 99.1 BELLICUM PHARMACEUTICALS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: APRIL 22, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2019 1. GENERAL. (a) Successor to and Continuation of 2014 Plan. (i) The Plan is intended as the successor to and continuation of the Bellicum Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amende
June 24, 2019	S-8	June 24, 2019 (File No. 333-232304) Form S-8 As filed with the Securities and Exchange Commission on June 24, 2019 Registration No.
June 19, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 Bellicum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36783 20-1450200 (State or other jurisdiction of incorporation) (C

BLCM / Bellicum Pharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)